Essential Partners’s Candel Therapeutics CADL Stock Holding History

Essential Partners’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$52	Hold	5	–	–	﹤0.01%	2763
2026 Q2	$52	Sell	5 -4	-44%	-$30	﹤0.01%	2788
2026 Q1	$44	Buy	+9	New	+$49	﹤0.01%	2790

Other funds holding CADL

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Essential Partners's CADL Position: Q3 2026 in Review

Essential Partners held its Candel Therapeutics (CADL) position steady in Q3 2026 at 5 shares worth $52. The position accounts for ﹤0.01% of the portfolio, ranked #2763.

Essential Partners first reported a position in CADL in Q1 2026 and has held it in 3 quarters since. 5 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

Essential Partners held 5 shares of Candel Therapeutics worth $52 as of Q3 2026.
Essential Partners left its Candel Therapeutics share count unchanged in Q3 2026.
Candel Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2763 holding.
Essential Partners first reported a position in Candel Therapeutics in Q1 2026 and has held it in 3 quarters since.
5 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.